Brensocatib becomes first licensed treatment for non‑cystic fibrosis bronchiectasis - PharmaTimes MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups

#PharmaTimes #pharma #pharmaceuticals #Brensocatib #Brinsupri #noncysticfibrosisbronchiectasis #MHRA #MedicinesandHealthcareproductsRegulatoryAgency #marketingauthorisation #chroniccondition #dipeptidylpeptidase1 #inflammatoryprocess #lungs #respiratory #JulianBeach
zurl.co/LPYPc

Gedeon Richter UK takes over UK rights to cariprazine - PharmaTimes Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati

#mentalhealth #GedeonRichter #UK #cariprazine #neuropsychiatry #marketingtransfer #Recordati #GedeonRichterUK #RecordatiPharmaceuticals #UKpromotion #MarketingAuthorisation #schizophrenia #adults #centralnervoussystem #CNS #chronicmentalhealthcondition
zurl.co/pROEi

European Commission approves ROMVIMZA for TGCT treatment - PharmaTimes Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU

#ROMVIMZA #Vimseltinib #TGCTtreatment #tenosynovialgiantcelltumour #EU #symptomatictenosynovialgiantcelltumour #TGCT #marketingauthorisation #TGCTtherapy #OnoPharmaceutical #Deciphera #phase3MOTIONstudy #Secondaryendpoints #tumourresponse #stiffness #qualityoflife
pharmatimes.com/news/europea...

Moderna wins EU approval for updated COVID-19 vaccine - PharmaTimes Spikevax authorised to target LP.8.1 variant ahead of 2025-2026 season

#vaccines #Moderna #COVID19vaccine #Spikevax #LP81variant #marketingauthorisation #updatedCOVID19vaccine #SARSCoV2variantLP81 #EuropeanMedicinesAgency #EMA #20252026vaccinationseason #eligiblepopulations #globalhealthauthorities #ModernaCOVID19vaccines
pharmatimes.com/news/moderna...

Access To New Medicines In The English NHS | The King's Fund Have you ever wondered how new medicines are developed, approved and priced? This explainer outlines the long journey from the discovery of a new drug to when it becomes available on the NHS.

#Accesstonewmedicines #NHSFunding #Integratedcare #NICE #ABPI #lifesciences #Marketingauthorisation #EAMS #QALYs #ICER #HST #BIT #DHSC #VPAG #VPAS #PPRS #ATMPs #HTA #formularies #clinicalpathways #ICBs #IMOC #medicaldevices #medicalappliances #wounddressings
www.kingsfund.org.uk/insight-and-...

EC approves Santen’s Ryjunea to slow progression of paediatric myopia - PharmaTimes Therapy indicated for children aged 3 to 14 at treatment initiation

#ophthalmology #optics #eyehealth #Santen #Ryjunea #paediatricmyopia #childhoodmyopia #marketingauthorisation #atropineeyedrop #childhoodeyecare #managingmyopia #children #myopiaprogression #SydnexisInc #phase3starstudy #shortsightedness #severeeyeconditions
pharmatimes.com/news/europea...

NICE recommends mirikizumab for Crohn's disease treatment - PharmaTimes New guidance expands treatment options for eligible patients

#gastro #immunology #gastroenterology #mirikizumab #Omvoh #EliLilly #Crohnsdisease #Crohnsdiseasetreatment #NICE #NICEfinaldraftguidance #MHRA #marketingauthorisation #VIVID1clinicaltrial #clinicalremission #inflammatoryboweldisease #CrohnsandColitisUK
pharmatimes.com/news/nice-re...

Amgen’s Tepezza granted marketing authorisation in the UK - PharmaTimes Teprotumumab approved as first targeted treatment for thyroid eye disease

#thyroideyedisease #TED #Amgen #Tepezza #Teprotumumab #Gravesophthalmopath #GravesEyeDisease #autoimmunedisorder #overactivethyroid #marketingauthorisation #MHRA #immunotherapy #insulinlikegrowthfactor1receptor #IGF1R #phase3OPTICtrial #OPTICtrial #proptosis
pharmatimes.com/news/amgens-...

AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis - PMLiVE The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

#AbbVie #Rinvoq #upadacitinib #giantcellarteritis #oralJAKinhibitor #JAKinhibitor #marketingauthorisation #Januskinaseinhibitor #SELECTGCAtrial #immunology #pharma #pharmaceuticals
zurl.co/ovP8I